Remarkably, a good efficacy of this inhibitor was observed in NSCLC devoid of PIK3CA gene mutations, but with constitutive activation of the PI3K/AKT pathway in vitro and in vivo. This evidence concerns the gene PIK3CB and non-small cell lung carcinoma.